Clinical management of urticaria using omalizumab: The first licensed biological therapy available for chronic spontaneous urticaria

A. M. Giménez-Arnau, E. Toubi, A. M. Marsland, M. Maurer

Research output: Contribution to journalReview articleResearchpeer-review

36 Citations (Scopus)

Abstract

© 2016 European Academy of Dermatology and Venereology. This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to/who remain symptomatic despite H1-antihistamine treatment, and has demonstrated good efficacy and safety in the clinical trial setting. Real-life clinical experience with omalizumab can be explored to address important practical questions relating to its use in CSU patients. Some experts have proposed that a consensus algorithm, covering various aspects to consider when using omalizumab in real-life clinical practice for the management of CSU, could answer many of these questions.
Original languageEnglish
Pages (from-to)25-32
JournalJournal of the European Academy of Dermatology and Venereology
Volume30
DOIs
Publication statusPublished - 1 Jul 2016

Fingerprint Dive into the research topics of 'Clinical management of urticaria using omalizumab: The first licensed biological therapy available for chronic spontaneous urticaria'. Together they form a unique fingerprint.

Cite this